Dorothea C Torti1, Brock C Christensen2, Craig A Storm3, Joan Fortuny4, Ann E Perry3, Michael S Zens5, Therese Stukel6, Steven K Spencer1, Heather H Nelson7, Margaret R Karagas8. 1. Section of Dermatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. 2. Department of Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island; Department of Community Health, Center for Environmental Health and Technology, Brown University, Providence, Rhode Island. 3. Department of Pathology, Dartmouth Medical School, Hanover, New Hampshire. 4. Novartis Farmaceutica SA, Barcelona, Spain. 5. Section of Biostatistics and Epidemiology, Dartmouth Medical School, Hanover, New Hampshire. 6. Section of Biostatistics and Epidemiology, Dartmouth Medical School, Hanover, New Hampshire; Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada. 7. Division of Epidemiology and Community Health, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. 8. Section of Biostatistics and Epidemiology, Dartmouth Medical School, Hanover, New Hampshire. Electronic address: Margaret.Karagas@Dartmouth.edu.
Abstract
BACKGROUND: Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are potentially chemopreventive. OBJECTIVE: We examined the relation between NSAID use and nonmelanoma skin cancer in a population-based case-control study. METHODS: NSAID and analgesic use was analyzed in 1484 participants: 535 with squamous cell carcinoma (SCC), 487 with basal cell carcinoma (BCC), and 462 control subjects. RESULTS: Use of NSAIDs, particularly aspirin, was associated with a reduced odds ratio (OR) of SCC, especially tumors positive for p53 (OR 0.29; 95% confidence interval 0.11-0.79) or with PTCH loss of heterozygosity (OR 0.35; 95% confidence interval 0.13-0.96). Although not considered a NSAID, decreased ORs of both basal cell carcinoma and SCC were observed in relation to use of paracetamol (acetaminophen). Risk of BCC was unrelated to NSAID use. LIMITATIONS: Self-reported drug use was a limitation. CONCLUSIONS: This study supports the hypothesis that NSAIDs, aspirin in particular, may reduce risk of SCC and may affect specific molecular subtypes of SCC.
BACKGROUND:Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are potentially chemopreventive. OBJECTIVE: We examined the relation between NSAID use and nonmelanoma skin cancer in a population-based case-control study. METHODS: NSAID and analgesic use was analyzed in 1484 participants: 535 with squamous cell carcinoma (SCC), 487 with basal cell carcinoma (BCC), and 462 control subjects. RESULTS: Use of NSAIDs, particularly aspirin, was associated with a reduced odds ratio (OR) of SCC, especially tumors positive for p53 (OR 0.29; 95% confidence interval 0.11-0.79) or with PTCH loss of heterozygosity (OR 0.35; 95% confidence interval 0.13-0.96). Although not considered a NSAID, decreased ORs of both basal cell carcinoma and SCC were observed in relation to use of paracetamol (acetaminophen). Risk of BCC was unrelated to NSAID use. LIMITATIONS: Self-reported drug use was a limitation. CONCLUSIONS: This study supports the hypothesis that NSAIDs, aspirin in particular, may reduce risk of SCC and may affect specific molecular subtypes of SCC.
Authors: J Toguchida; T Yamaguchi; B Ritchie; R L Beauchamp; S H Dayton; G E Herrera; T Yamamuro; Y Kotoura; M S Sasaki; J B Little Journal: Cancer Res Date: 1992-11-15 Impact factor: 12.701
Authors: Warner B Bair; Nancy Hart; Janine Einspahr; Guangming Liu; Zigang Dong; David Alberts; G Tim Bowden Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-12 Impact factor: 4.254
Authors: Karen Blohm-Mangone; Nichole B Burkett; Shekha Tahsin; Paul B Myrdal; Alhassan Aodah; Brenda Ho; Jaroslav Janda; Michelle McComas; Kathylynn Saboda; Denise J Roe; Zigang Dong; Ann M Bode; Emanuel F Petricoin; Valerie S Calvert; Clara Curiel-Lewandrowski; David S Alberts; Georg T Wondrak; Sally E Dickinson Journal: Cancer Prev Res (Phila) Date: 2018-02-01
Authors: Lawrence Fitzgerald Kuklinski; Michael Scot Zens; Ann E Perry; Adele C Green; Margaret R Karagas Journal: Photodermatol Photoimmunol Photomed Date: 2017-01-17 Impact factor: 3.135
Authors: Karin A Vineretsky; Margaret R Karagas; Brock C Christensen; Jacquelyn K Kuriger-Laber; Ann E Perry; Craig A Storm; Heather H Nelson Journal: Cancer Res Date: 2016-01-07 Impact factor: 12.701
Authors: Dorothea T Barton; Michael S Zens; Heather H Nelson; Brock C Christensen; Craig A Storm; Ann E Perry; Margaret R Karagas Journal: J Invest Dermatol Date: 2015-11-18 Impact factor: 8.551
Authors: Sarah N Robinson; Michael S Zens; Ann E Perry; Steven K Spencer; Eric J Duell; Margaret R Karagas Journal: J Invest Dermatol Date: 2013-01-23 Impact factor: 8.551